Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  The Lancet

• Publication date

  2011-06-25

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0140-6736(11)60764-2PMID 21665265
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• 5-year follow-up after primary percutaneous coronary intervention with a paclitaxel-eluting stent versus a bare-metal stent in acute ST-segment elevation myocardial infarction: a follow-up study of the PASSION (Paclitaxel-Eluting Versus Conventional Stent in Myocardial Infarction with ST-Segment Ele

  2011cited by this paper
• Four-year follow-up of TYPHOON (trial to assess the use of the CYPHer sirolimus-eluting coronary stent in acute myocardial infarction treated with BallOON angioplasty).

  2011cited by this paper
• Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial.

  2010cited by this paper
• Heart disease and stroke statistics--2010 update: a report from the American Heart Association.

  2010cited by this paper
• Ticagrelor Versus Clopidogrel in Patients With ST-Elevation Acute Coronary Syndromes Intended for Reperfusion With Primary Percutaneous Coronary Intervention: A Platelet Inhibition and Patient Outcomes (PLATO) Trial Subgroup Analysis

  2010cited by this paper
• Three-year outcome of sirolimus-eluting versus bare-metal stents for the treatment of ST-segment elevation myocardial infarction (from the MISSION! Intervention Study).

  2010cited by this paper
• A risk score to predict bleeding in patients with acute coronary syndromes.

  2010cited by this paper
• Prognostic Modeling of Individual Patient Risk and Mortality Impact of Ischemic and Hemorrhagic Complications: Assessment From the Acute Catheterization and Urgent Intervention Triage Strategy Trial

  2010cited by this paper
• [Commentary to the article: Kedhi E, Joesoef KS, McFadden E et al. Second-generation everolimus- -eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial. Lancet, 2010; 375: 201-209].

  2010cited by this paper
• Long-term outcome after drug-eluting versus bare-metal stent implantation in patients with ST-segment elevation myocardial infarction: 3-year follow-up of the randomized DEDICATION (Drug Elution and Distal Protection in Acute Myocardial Infarction) Trial.

  2010cited by this paper
• Maintenance of long-term clinical benefit with sirolimus-eluting stents in patients with ST-segment elevation myocardial infarction 3-year results of the SESAMI (sirolimus-eluting stent versus bare-metal stent in acute myocardial infarction) trial.

  2010cited by this paper
• Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease.

  2010cited by this paper
• Safety and effectiveness of bivalirudin in routine care of patients undergoing percutaneous coronary intervention.

  2010cited by this paper
• Executive summary: heart disease and stroke statistics--2010 update: a report from the American Heart Association.

  2010cited by this paper
• Selection criteria for drug-eluting versus bare-metal stents and the impact of routine angiographic follow-up: 2-year insights from the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial.

  2010cited by this paper
• Use of drug-eluting stents in acute myocardial infarction: a systematic review and meta-analysis.

  2009cited by this paper
• Reperfusion therapy for ST elevation acute myocardial infarction in Europe: description of the current situation in 30 countries

  2009cited by this paper
• Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial.

  2009cited by this paper
• Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction.

  2009cited by this paper
• Long-Term outcome of drug-eluting stents compared with bare metal stents in ST-segment elevation myocardial infarction: results of the paclitaxel- or sirolimus-eluting stent versus bare metal stent in Primary Angioplasty (PASEO) Randomized Trial.

  2009cited by this paper
• 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST‐Elevation Myocardial Infarction (Updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (Updating the 2005 Guideline and 2007 Focused Update)

  2009cited by this paper
• Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.

  2009cited by this paper
• Bivalirudin during primary PCI in acute myocardial infarction.

  2008cited by this paper
• Delayed Arterial Healing and Increased Late Stent Thrombosis at Culprit Sites After Drug-Eluting Stent Placement for Acute Myocardial Infarction Patients: An Autopsy Study

  2008cited by this paper
• Antiplatelet Therapy Use After Discharge Among Acute Myocardial Infarction Patients With In-Hospital Bleeding

  2008cited by this paper
• Coronary stenting versus balloon angioplasty for acute myocardial infarction: a meta-regression analysis of randomized trials.

  2008cited by this paper
• The Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial: study design and rationale.

  2008cited by this paper
• Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology.

  2008cited by this paper
• Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial.

  2008cited by this paper
• Decline in rates of death and heart failure in acute coronary syndromes, 1999-2006.

  2007cited by this paper
• Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American D

  2007cited by this paper
• Current incidence and clinical outcomes of bivalirudin administration among patients undergoing primary coronary intervention for stent thrombosis elevation acute myocardial infarction

  2007cited by this paper
• Comparison between stenting and balloon in elderly patients undergoing primary angioplasty for ST-segment elevation myocardial infarction.

  2007cited by this paper
• Proinflammatory, immunomodulating, and prothrombotic properties of anemia and red blood cell transfusions

  2006cited by this paper
• Adverse Impact of Bleeding on Prognosis in Patients With Acute Coronary Syndromes

  2006cited by this paper
• Prevalence, Predictors, and Outcomes of Premature Discontinuation of Thienopyridine Therapy After Drug-Eluting Stent Placement: Results From the PREMIER Registry

  2006cited by this paper
• Comparison of fondaparinux and enoxaparin in acute coronary syndromes.

  2006cited by this paper
• Three-year duration of benefit from abciximab in patients receiving stents for acute myocardial infarction in the randomized double-blind ADMIRAL study.

  2005cited by this paper
• Hemodynamic oxygen transport and 2,3-diphosphoglycerate changes after transfusion of patients in acute respiratory failure

  2004cited by this paper
• Five-year outcome of patients with acute myocardial infarction enrolled in a randomised trial assessing the value of abciximab during coronary artery stenting.

  2004cited by this paper
• Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes.

  2004cited by this paper
• ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients Wi

  2004cited by this paper
• Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials.

  2003cited by this paper
• Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction.

  2002cited by this paper
• Impact of Alloantigens and Storage-associated Factors on Stimulated Cytokine Response in an In Vitro Model of Blood Transfusion

  2002cited by this paper
• Stored red blood cells selectively activate human neutrophils to release IL-8 and secretory PLA2.

  2000cited by this paper
• Impact of blood transfusions on inflammatory mediator release in patients undergoing cardiac surgery.

  1999cited by this paper
• Prediction of Creatinine Clearance from Serum Creatinine

  1976cited by this paper
• Prediction of creatinine clearance from serum creatinine.

  1975cited by this paper

• Precision Management of Coronary Stent Thrombosis: A Contemporary Guide

  2026cites this paper
• Artificial intelligence-enabled electrocardiography from scientific research to clinical application

  2025cites this paper
• Efficacy and Safety of Deferred Stenting in Geriatric Patients with STEMI and High Thrombus Burden

  2024cites this paper
• The IMproving Preclinical Assessment of Cardioprotective Therapies (IMPACT): multicenter pig study on the effect of ischemic preconditioning

  2024cites this paper
• Bivalirudin versus heparin in ST and non-ST-segment elevation myocardial infarction-Outcomes at two years.

  2024cites this paper
• Hirudin in the Treatment of Chronic Kidney Disease

  2024cites this paper
• Differential impact of fentanyl and morphine doses on ticagrelor-induced platelet inhibition in ST-segment elevation myocardial infarction: a subgroup analysis from the PERSEUS randomized trial

  2024cites this paper
• Anatomy-Informed Multimodal Learning for Myocardial Infarction Prediction

  2023cites this paper
• Five-Year Efficacy and Safety of TiNO-Coated Stents Versus Drug-Eluting Stents in Acute Coronary Syndrome: A Meta-Analysis

  2023cites this paper
• Bivalirudin versus unfractionated heparin in patients with myocardial infarction undergoing percutaneous coronary intervention: A systematic review and meta-analysis of randomized controlled trials.

  2023cites this paper
• Efficacy and Safety of the Reduced Bivalirudin in Patients Undergoing Coronary Angiography or Percutaneous Coronary Intervention Stratified by Renal Function (REDUCE BOLUS): A Single-Blind, Stratified Randomized, Non-inferiority Trial

  2022cites this paper
• Occurrence and Risk Factors of Adverse Drug Reactions in Patients Receiving Bivalirudin as Anticoagulant During Percutaneous Coronary Intervention: A Prospective, Multi-Center, Intensive Monitoring Study

  2022cites this paper
• Unravelling the role of macrophages in cardiovascular inflammation through imaging: a state-of-the-art review

  2022cites this paper
• Anaemia and acute coronary syndrome: A complex clinical scenario.

  2022cites this paper
• Comparison of Drug-Coated Balloons and Drug-Eluting Stents in Primary Percutaneous Coronary Interventions for ST-Segment Elevated Myocardial Infarction: A Systemic Review and Meta-Analysis

  2022cites this paper
• Outpatient cardiac rehabilitation dose after acute coronary syndrome in a nationwide cohort

  2022cites this paper
• Radial Artery Access for Acute Coronary Syndromes: a Review of Current Evidence

  2022cites this paper
• Bivalirudin vs. heparin on a background of ticagrelor and aspirin in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: A multicenter prospective cohort study

  2022cites this paper
• Incidence, Predictors, and Outcomes of Acute and Sub-acute Stent Thrombosis after Emergency Percutaneous Coronary Revascularization with Drug-Eluting Stents: A Prospective Observational Study

  2022cites this paper
• A Meta-analysis of Clinical Trials Evaluating the Impact of Bivalirudin-based Anticoagulation for Primary Percutaneous Coronary on Long-Term Mortality

  2021cites this paper
• Management of ST Elevation Myocardial Infarction (STEMI) in Different Settings

  2021cites this paper
• Bivalirudin and sirolimus co-eluting coronary stent: Potential strategy for the prevention of stent thrombosis and restenosis.

  2021cites this paper
• Bivalirudin in Primary PCI: Can Its Glory Being Restored?

  2021cites this paper
• Clinical risk scores: a tool to understand bleeding and thrombotic risk

  2021cites this paper
• Study on the safety and effectiveness of drug-coated balloons in patients with acute myocardial infarction

  2021cites this paper
• A neural system dynamics modeling platform and its applications in randomized controlled trial data analysis

  2021cites this paper
• Periprocedural Antithrombotic Treatment in Complex Percutaneous Coronary Intervention

  2021cites this paper
• 10-Year Follow-Up of Patients With Everolimus-Eluting Versus Bare-Metal Stents After ST-Segment Elevation Myocardial Infarction.

  2021cites this paper
• Twelve-month mortality from the "How Effective are Antithrombotic Therapies in Primary Percutaneous Coronary Intervention (HEAT-PPCI) Trial".

  2020cites this paper
• The Rise of Transradial Artery Access for Percutaneous Coronary Intervention in Patients with Acute Coronary Syndromes in Australia

  2020cites this paper
• Modern Management of ST-Segment Elevation Myocardial Infarction.

  2020cites this paper
• Antithrombotic regimens for percutaneous coronary intervention of the left main coronary artery: The EXCEL trial

  2020influential citation
• Safety and Efficacy of Femoral Access vs Radial Access in ST-Segment Elevation Myocardial Infarction: The SAFARI-STEMI Randomized Clinical Trial.

  2020cites this paper
• Drug Eluting Stents versus Bare Metal Stents in ST- Segment Elevation Myocardial Infarction

  2019cites this paper
• Assessment of residual thrombus burden in patients with ST‐segment elevation myocardial infarction undergoing bivalirudin versus unfractionated heparin infusion: The MATRIX (minimizing adverse hemorrhagic events by transradial access site and angioX) OCT study

  2019cites this paper
• Perioperative ST-elevation myocardial infarction: with time of the essence, is there a case for guidelines?

  2019cites this paper
• A systematic review and meta-analysis of bivalirudin application in peripheral endovascular procedures.

  2019cites this paper
• Comparison of Clinical Outcomes: Bivalirudin With Transfemoral Access Versus Heparin With Transradial Access in Patients With ST segment Elevation Myocardial Infarction.

  2019cites this paper
• Optimal Antithrombotic Therapy for Patients with STEMI Undergoing PCI at High Risk of Bleeding

  2019cites this paper
• Safety and Efficacy of Periprocedural Heparin Plus a Short-Term Infusion of Tirofiban Versus Bivalirudin Monotherapy in Patients Who Underwent Percutaneous Coronary Intervention (from the Intermountain Heart Institute STAIR Observational Registry).

  2019cites this paper
• Meta-Analysis of the Role of Cangrelor for Patients Undergoing Percutaneous Coronary Intervention.

  2019cites this paper
• ST-segment elevation myocardial infarction

  2019cites this paper
• 2019 Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology Guidelines on the Acute Management of ST-Elevation Myocardial Infarction: Focused Update on Regionalization and Reperfusion.

  2019cites this paper
• The link between anemia and adverse outcomes in patients with acute coronary syndrome

  2019cites this paper
• Characteristics and outcomes of patients requiring bailout use of glycoprotein IIb/IIIa inhibitors for thrombotic complications of percutaneous coronary intervention: An analysis from the CHAMPION PHOENIX trial.

  2019cites this paper
• Relative survival and excess mortality following primary percutaneous coronary intervention for ST-elevation myocardial infarction

  2019cites this paper
• Efficacy and Safety of Glycoprotein IIb/IIIa Inhibitors on Top of Ticagrelor in STEMI: A Subanalysis of the ATLANTIC Trial

  2019cites this paper
• Efficacy and safety of bivalirudin during percutaneous coronary intervention in high‐bleeding‐risk elderly patients with chronic total occlusion: A prospective randomized controlled trial

  2019cites this paper
• Systematic Incorporation of Sex‐Specific Information Into Clinical Practice Guidelines for the Management of ST‐Segment–Elevation Myocardial Infarction: Feasibility and Outcomes

  2019cites this paper
• Bivalirudin versus heparin with primary percutaneous coronary intervention

  2018cites this paper
• Acute ST-Segment Elevation Myocardial Infarction (STEMI)

  2018cites this paper
• Optimal pharmacological therapy in ST-elevation myocardial infarction—a review

  2018cites this paper
• Non-ST-Segment Elevation Acute Coronary Syndromes (NSTE-ACS)

  2018cites this paper
• Anticoagulants from Hematophagous

  2018cites this paper
• Efficacy and safety of bivalirudin in coronary artery disease patients with mild to moderate chronic kidney disease: Meta-analysis.

  2018cites this paper
• Predictive Value of CHA2DS2-VASc Score for Ischemic Events in Patients Undergoing Percutaneous Coronary Intervention

  2018cites this paper
• Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial.

  2018cites this paper
• Management of established coronary artery disease in aircrew with previous myocardial infarction or revascularisation

  2018cites this paper
• Long-term safety of bioresorbable scaffolds: insights from a network meta-analysis including 91 trials.

  2018cites this paper
• Serum gamma-glutamyl transferase is a predictor of mortality in patients with acute myocardial infarction

  2018cites this paper
• Bivalirudin versus heparin in percutaneous coronary intervention-a systematic review and meta-analysis of randomized trials stratified by adjunctive glycoprotein IIb/IIIa strategy.

  2018cites this paper
• Management des akuten Koronarsyndroms

  2018cites this paper
• Anticoagulation in Acute Coronary Syndrome-State of the Art.

  2018cites this paper
• The effect of intracoronary infusion of bone marrow‐derived mononuclear cells on all‐cause mortality in acute myocardial infarction: rationale and design of the BAMI trial

  2017cites this paper
• Bivalirudin versus Heparin plus Glycoprotein IIb/IIIa Inhibitors in Women Undergoing Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Controlled Trials

  2017cites this paper
• Impact of anticoagulation strategy with bivalirudin or heparin on nonaccess site bleeding in percutaneous coronary interventions: A meta‐analysis of randomized trials

  2017cites this paper
• Drug-eluting stents versus bare-metal stents for acute coronary syndrome.

  2017cites this paper
• Selective use of contemporary drug-eluting stents in primary angioplasty for ST-elevation myocardial infarction: pooled analysis of COMFORTABLE AMI and EXAMINATION.

  2017cites this paper
• Five-year outcomes of ST-elevation myocardial infarction versus non-ST-elevation acute coronary syndrome treated with biodegradable polymer-coated sirolimus-eluting stents: Insights from the CREATE trial.

  2017cites this paper
• Contemporary Management of ST-Elevation Myocardial Infarction.

  2017cites this paper
• Antithrombotic therapy for patients with STEMI undergoing primary PCI

  2017cites this paper
• Comparison of Outcomes and Prognosis of Patients With Versus Without Newly Diagnosed Diabetes Mellitus After Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction (the HORIZONS-AMI Study).

  2017cites this paper
• One-Year Mortality for Bivalirudin vs Heparins Plus Optional Glycoprotein IIb/IIIa Inhibitor Treatment Started in the Ambulance for ST-Segment Elevation Myocardial Infarction: A Secondary Analysis of the EUROMAX Randomized Clinical Trial

  2017cites this paper
• Comparison of anticoagulant and antiplatelet therapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention ( PCI )

  2017cites this paper
• Anticoagulants in STEMI Interventions

  2017cites this paper
• Long-term Outcomes of Primary Percutaneous Coronary Intervention with Second-generation Drug-eluting Stents in ST-elevation Myocardial Infarction Patients Caused by Very Late Stent Thrombosis

  2017cites this paper
• Antithrombotic therapy before, during and after emergency angioplasty for ST elevation myocardial infarction

  2017cites this paper
• In-Hospital Outcome Comparing Bivalirudin to Heparin in Real-World Primary Percutaneous Coronary Intervention.

  2017cites this paper
• Atrial Fibrillation on Vitamin K Antagonist Undergoing Urgent Percutaneous Coronary Intervention for Non-ST-Elevation Acute Coronary Syndrome

  2017cites this paper
• Interventional Treatment of Acute Coronary Syndrome: ST-Segment Elevation Myocardial Infarction (STEMI)

  2017cites this paper
• Effect of post‐primary percutaneous coronary intervention bivalirudin infusion on net adverse clinical events and mortality: A comprehensive pairwise and network meta‐analysis of randomized controlled trials

  2017cites this paper
• Bivalirudin in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: uncertainties almost clarified.

  2017cites this paper
• Choice of Stent in STEMI Interventions

  2017cites this paper
• A Consecutive Series of all Subtypes of the Acute Coronary Syndrome Patient Admitted to an Academic Coronary Care Unit

  2017influential citation
• Is routine post-procedural anticoagulation warranted after primary percutaneous coronary intervention in ST-segment elevation myocardial infarction? Insights from the HORIZONS-AMI trial

  2017cites this paper
• Management des akuten Koronarsyndroms ohne ST-Strecken-Hebung

  2017cites this paper
• Bivalirudin versus heparin in women undergoing percutaneous coronary intervention: A systematic review and meta-analysis of randomized clinical trials.

  2017cites this paper
• Safety, efficiency and cost effectiveness of Bivalirudin: A systematic review

  2017cites this paper
• Role of Calcium in Platelet Activation: Novel Insights and Pharmacological Implications.

  2016cites this paper
• Impact of bivalirudin on mortality and bleeding complications in acute coronary syndrome patients undergoing invasive revascularization

  2016cites this paper
• Impact of anticoagulation regimen prior to revascularization in patients with non‐ST‐segment elevation acute coronary syndromes: The ACUITY trial

  2016cites this paper
• Clinical outcomes in patients with ST-segment elevation myocardial infarction treated with everolimus-eluting stents versus bare-metal stents (EXAMINATION): 5-year results of a randomised trial.

  2016cites this paper
• Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A North American Perspective-2016 Update.

  2016cites this paper
• A mixed treatment comparison for short- and long-term outcomes of bare-metal and drug-eluting coronary stents.

  2016cites this paper
• Effects Of Glycoprotein IIb/IIIa Antagonists: Anti Platelet Aggregation And Beyond.

  2016cites this paper
• Bivalirudin in Patients Undergoing PCI: State of Art and Future Perspectives.

  2016cites this paper
• One‐year cardiovascular outcomes of drug‐eluting stent versus bare‐metal stent implanted in diabetic patients with acute coronary syndrome

  2016cites this paper
• Heparin Versus Bivalirudin Monotherapy in the Setting of Primary Percutaneous Coronary Intervention for Patients With ST-Segment Elevation Myocardial Infarction

  2016influential citation
• Controversies in the Management of ST Elevation Myocardial Infarction: Thrombin Inhibition.

  2016cites this paper
• Current Role of Platelet Glycoprotein IIb/IIIa Inhibition in the Therapeutic Management of Acute Coronary Syndromes in the Stent Era

  2016cites this paper